Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (215)	6/14/2001 12:56:23 PM
From: Jim Oravetz	Read Replies (1) of 278

Axonyx: Its Drug May Treat Underlying Cause Of Alzheimer's Dow Jones Newswires NEW YORK -- Axonyx Inc. (AXYX) released research on Phenserine suggesting that the drug may be effective in slowing the progression of Alzheimer's disease. The research was published in the Proceedings of the National Academy of Sciences. In a press release Thursday, the company said the study showed a 14% reduction after 8 hours and a 31% reduction after 16 hours in beta-amyloid levels in cells treated with Phenserine. The Alzheimer's drug aims to inhibit the production of beta-amyloid protein, which if allowed to accumulate becomes a brain clogging plaque. Shares of Axonyx recently traded at $5.25, up 45 cents, or 9.4%, on Nasdaq volume of 92,300 shares. Average daily volume is 25,704 shares. Axonyx develops pharmaceutical compounds and technologies used to treat Alzheimer's disease, other memory disorders and Mad Cow disease.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next